List of bibliographic references
Number of relevant bibliographic references: 8.
| Ident. | Authors (with country if any) | Title |
|---|
| 000118 (2017) |
Tarik Asselah [France] ; Stefan Bourgeois [Belgique] ; Stephen Pianko [Australie] ; Stefan Zeuzem [Allemagne] ; Mark Sulkowski [États-Unis] ; Graham R. Foster [Royaume-Uni] ; Lingling Han [États-Unis] ; John Mcnally [États-Unis] ; Anu Osinusi [États-Unis] ; Diana M. Brainard [États-Unis] ; G Mani Subramanian [États-Unis] ; Edward J. Gane [Nouvelle-Zélande] ; Jordan J. Feld [Canada] ; Alessandra Mangia [Italie] | Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis. |
| 000210 (2017) |
Tania M. Welzel [Allemagne] ; Tarik Asselah [France] ; Emily O. Dumas [États-Unis] ; Stefan Zeuzem [Allemagne] ; David Shaw [Australie] ; Rawi Hazzan [Israël] ; Xavier Forns [Espagne] ; Tami Pilot-Matias [États-Unis] ; Wenjing Lu [États-Unis] ; Daniel E. Cohen [États-Unis] ; Jordan J. Feld [Canada] | Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial. |
| 000404 (2017) |
Ira M. Jacobson [États-Unis] ; Eric Lawitz [États-Unis] ; Edward J. Gane [Nouvelle-Zélande] ; Bernard E. Willems [Canada] ; Peter J. Ruane [États-Unis] ; Ronald G. Nahass [États-Unis] ; Sergio M. Borgia [Canada] ; Stephen D. Shafran [Canada] ; Kimberly A. Workowski [Géorgie (pays)] ; Brian Pearlman [Géorgie (pays)] ; Robert H. Hyland [États-Unis] ; Luisa M. Stamm [États-Unis] ; Evguenia Svarovskaia [États-Unis] ; Hadas Dvory-Sobol [États-Unis] ; Yanni Zhu [États-Unis] ; G Mani Subramanian [États-Unis] ; Diana M. Brainard [États-Unis] ; John G. Mchutchison [États-Unis] ; Norbert Br U [États-Unis] ; Thomas Berg [Allemagne] ; Kosh Agarwal [Royaume-Uni] ; Bal Raj Bhandari [États-Unis] ; Mitchell Davis [États-Unis] ; Jordan J. Feld [Canada] ; Gregory J. Dore [Australie] ; Catherine A M. Stedman [Nouvelle-Zélande] ; Alexander J. Thompson [Australie] ; Tarik Asselah [France] ; Stuart K. Roberts [Australie] ; Graham R. Foster [Royaume-Uni] | Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials. |
| 000A68 (2016) |
Tarik Asselah [France] ; Alex J. Thompson [Australie] ; Robert Flisiak [Pologne] ; Manuel Romero-Gomez [Espagne] ; Diethelm Messinger [Allemagne] ; Georgios Bakalos [Suisse] ; Mitchell L. Shiffman [États-Unis] | A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin |
| 000D36 (2015) |
Stefan Zeuzem [Allemagne] ; Vicente Soriano [Espagne] ; Tarik Asselah [France] ; Edward J. Gane [Nouvelle-Zélande] ; Jean-Pierre Bronowicki [France] ; Peter Angus [Australie] ; Ansgar W. Lohse [Allemagne] ; Felix Stickel [Suisse] ; Beat Müllhaupt [Suisse] ; Stuart Roberts [Australie] ; Marcus Schuchmann [Allemagne] ; Michael Manns [Allemagne] ; Marc Bourlière [France] ; Maria Buti [Espagne] ; Jerry O. Stern [États-Unis] ; John-Paul Gallivan [Allemagne] ; Florian Voss [Allemagne] ; John P. Sabo [États-Unis] ; Wulf Böcher [Allemagne] ; Federico J. Mensa [États-Unis] | Efficacy and Safety of Faldaprevir, Deleobuvir, and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis C Virus Infection and Advanced Liver Fibrosis or Cirrhosis |
| 000E58 (2015) |
Tarik Asselah [France] ; Stefan Zeuzem [Allemagne] ; Vicente Soriano [Espagne] ; Jean-Pierre Bronowicki [France] ; Ansgar W. Lohse [Allemagne] ; Beat Müllhaupt [Suisse] ; Marcus Schuchmann [Allemagne] ; Marc Bourlière [France] ; Maria Buti [Espagne] ; Stuart K. Roberts [Australie] ; Edward J. Gane [Nouvelle-Zélande] ; Jerry O. Stern [États-Unis] ; Florian Voss [Allemagne] ; Patrick Baum [Allemagne] ; John-Paul Gallivan [Allemagne] ; Wulf O. Böcher [Allemagne] ; Federico J. Mensa [États-Unis] | ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection |
| 001522 (2013) |
Stefan Zeuzem [Allemagne] ; Vincent Soriano [Espagne] ; Tarik Asselah [France] ; Jean-Pierre Bronowicki [France] ; Ansgar W. Lohse [Allemagne] ; Beat Müllhaupt [Suisse] ; Marcus Schuchmann [Allemagne] ; Marc Bourliere [France] ; Maria Buti [Espagne] ; Stuart K. Roberts [Australie] ; Ed J. Gane [Nouvelle-Zélande] ; Jerry O. Stern [Canada] ; Richard Vinisko [Canada] ; George Kukolj [Canada] ; John-Paul Gallivan [Allemagne] ; Wulf-Otto Böcher [Allemagne] ; Federico J. Mensa [Canada] | Faldaprevir and Deleobuvir for HCV Genotype 1 Infection |
| 001523 (2013) |
Stefan Zeuzem [Allemagne] ; Tarik Asselah [France] ; Peter Angus [Australie] ; Jean-Pierre Zarski [France] ; Dominique Larrey [France] ; Beat Müllhaupt [Suisse] ; Ed Gane [Nouvelle-Zélande] ; Marcus Schuchmann [Allemagne] ; Ansgar W. Lohse [Allemagne] ; Stanislas Pol [France] ; Jean-Pierre Bronowicki [France] ; Stuart Roberts [Australie] ; Keikawus Arasteh [Allemagne] ; Fabien Zoulim [France] ; Markus Heim [Suisse] ; Jerry O. Stern [États-Unis] ; Gerhard Nehmiz [Allemagne] ; George Kukolj [Canada] ; Wulf O. Böcher [Allemagne] ; Federico J. Mensa [États-Unis] | Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results |
List of associated KwdEn.i
Nombre de
documents | Descripteur |
|---|
| 4 | Female |
| 4 | Genotype |
| 4 | Humans |
| 4 | Male |
| 4 | Middle Aged |
| 3 | Adult |
| 3 | Aged |
| 3 | Antiviral Agents (therapeutic use) |
| 3 | Hepatitis C, Chronic (drug therapy) |
| 3 | Young Adult |
| 2 | Adolescent |
| 2 | Aged, 80 and over |
| 2 | Antiviral Agents (administration & dosage) |
| 2 | Antiviral Agents (adverse effects) |
| 2 | Ribavirin (therapeutic use) |
| 2 | Typing |
| 2 | Viral hepatitis C |
| 1 | Acrylates (adverse effects) |
| 1 | Acrylates (pharmacology) |
| 1 | Acrylates (therapeutic use) |
| 1 | Anemia (diagnosis) |
| 1 | Anemia (etiology) |
| 1 | Antiviral |
| 1 | Antiviral Agents (pharmacology) |
| 1 | Benzimidazoles (adverse effects) |
| 1 | Benzimidazoles (pharmacology) |
| 1 | Benzimidazoles (therapeutic use) |
| 1 | Carbamates (administration & dosage) |
| 1 | Carbamates (adverse effects) |
| 1 | Carbamates (therapeutic use) |
| 1 | Deleobuvir |
| 1 | Drug Therapy, Combination |
| 1 | Faldaprevir |
| 1 | Hepacivirus (drug effects) |
| 1 | Hepacivirus (genetics) |
| 1 | Hepatitis C (complications) |
| 1 | Hepatitis C (drug therapy) |
| 1 | Hepatitis C (virology) |
| 1 | Hepatitis C virus |
| 1 | Hepatitis C, Chronic (complications) |
| 1 | Hepatitis C, Chronic (virology) |
| 1 | Heterocyclic Compounds, 4 or More Rings (administration & dosage) |
| 1 | Heterocyclic Compounds, 4 or More Rings (adverse effects) |
| 1 | Heterocyclic Compounds, 4 or More Rings (therapeutic use) |
| 1 | Interferon-alpha (administration & dosage) |
| 1 | Interferon-alpha (therapeutic use) |
| 1 | Interferons (metabolism) |
| 1 | Liver Cirrhosis (complications) |
| 1 | Liver Cirrhosis (drug therapy) |
| 1 | Macrocyclic Compounds (administration & dosage) |
| 1 | Macrocyclic Compounds (adverse effects) |
| 1 | Macrocyclic Compounds (therapeutic use) |
| 1 | Medicine |
| 1 | Models, Theoretical |
| 1 | Oligopeptides (adverse effects) |
| 1 | Oligopeptides (pharmacology) |
| 1 | Oligopeptides (therapeutic use) |
| 1 | Oral administration |
| 1 | Polyethylene Glycols (administration & dosage) |
| 1 | Polyethylene Glycols (therapeutic use) |
| 1 | Polymorphism, Single Nucleotide (genetics) |
| 1 | Pyrophosphatases (genetics) |
| 1 | Real-Time Polymerase Chain Reaction |
| 1 | Recombinant Proteins (administration & dosage) |
| 1 | Recombinant Proteins (therapeutic use) |
| 1 | Result |
| 1 | Retrospective Studies |
| 1 | Ribavirin |
| 1 | Ribavirin (administration & dosage) |
| 1 | Ribavirin (adverse effects) |
| 1 | Ribavirin (pharmacology) |
| 1 | Sofosbuvir (administration & dosage) |
| 1 | Sofosbuvir (adverse effects) |
| 1 | Sofosbuvir (therapeutic use) |
| 1 | Sulfonamides (administration & dosage) |
| 1 | Sulfonamides (adverse effects) |
| 1 | Sulfonamides (therapeutic use) |
| 1 | Sustained Virologic Response |
| 1 | Thiazoles (adverse effects) |
| 1 | Thiazoles (pharmacology) |
| 1 | Thiazoles (therapeutic use) |
| 1 | Viral Load |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Allemagne/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i -k "Tarik Asselah"
HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i \
-Sk "Tarik Asselah" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Allemagne/Analysis/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Allemagne
|étape= Analysis
|type= indexItem
|index= Author.i
|clé= Tarik Asselah
}}
| This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024 |  |
